牛牛AI助理已提取核心訊息
On January 5, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, announced the entry into warrant exercise agreements with existing accredited investors. The agreements pertain to the immediate exercise of outstanding warrants to purchase approximately 16.5 million shares of the company's common stock, which is expected to generate gross proceeds of about $5.0 million. The warrants include November 2023 Series B warrants and January 2023 warrants, with the latter's exercise price reduced from $1.55 to $0.3006 per share. The transaction is anticipated to close on or about January 9, 2024, subject to customary closing conditions. Avenue Therapeutics plans to issue new unregistered Series A and Series B warrants as consideration for the immediate cash exercise of the existing warrants. These new warrants will not be exercisable until stockholder...Show More
On January 5, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, announced the entry into warrant exercise agreements with existing accredited investors. The agreements pertain to the immediate exercise of outstanding warrants to purchase approximately 16.5 million shares of the company's common stock, which is expected to generate gross proceeds of about $5.0 million. The warrants include November 2023 Series B warrants and January 2023 warrants, with the latter's exercise price reduced from $1.55 to $0.3006 per share. The transaction is anticipated to close on or about January 9, 2024, subject to customary closing conditions. Avenue Therapeutics plans to issue new unregistered Series A and Series B warrants as consideration for the immediate cash exercise of the existing warrants. These new warrants will not be exercisable until stockholder approval is obtained to increase authorized shares and to comply with Nasdaq rules. The company has engaged Maxim Group LLC as the exclusive financial advisor and warrant solicitation agent for the transaction. Avenue Therapeutics intends to use the net proceeds for general corporate purposes and has committed to filing a registration statement with the SEC for the resale of the shares issuable upon exercise of the new warrants.
2024年1月5日，專業製藥公司Avenue Therapeutics, Inc. 宣佈與現有合格投資者簽訂認股權證行使協議。這些協議涉及立即行使未償認股權證，購買公司約1,650萬股普通股，預計將產生約500萬美元的總收益。認股權證包括2023年11月的B系列認股權證和2023年1月的認股權證，後者的行使價從每股1.55美元降至0.3006美元。該交易預計將於2024年1月9日左右完成，但須遵守慣例成交條件。Avenue Therapeutics計劃發行新的未註冊的A系列和B系列認股權證，作爲立即使用現有認股權證進行現金交易的對價。在獲得股東批准以增加授權股份並遵守納斯達克規則之前，這些新的認股權證將無法行使。該公司已聘請Maxim Group LLC作爲該交易的獨家財務顧問和認股權證招標代理。Avenue Therapeutics打算將淨收益用於一般公司用途，並承諾向美國證券交易委員會提交註冊聲明，轉售行使新認股權證後可發行的股票。
2024年1月5日，專業製藥公司Avenue Therapeutics, Inc. 宣佈與現有合格投資者簽訂認股權證行使協議。這些協議涉及立即行使未償認股權證，購買公司約1,650萬股普通股，預計將產生約500萬美元的總收益。認股權證包括2023年11月的B系列認股權證和2023年1月的認股權證，後者的行使價從每股1.55美元降至0.3006美元。該交易預計將於2024年1月9日左右完成，但須遵守慣例成交條件。Avenue Therapeutics計劃發行新的未註冊的A系列和B系列認股權證，作爲立即使用現有認股權證進行現金交易的對價。在獲得股東批准以增加授權股份並遵守納斯達克規則之前，這些新的認股權證將無法行使。該公司已聘請Maxim Group LLC作爲該交易的獨家財務顧問和認股權證招標代理。Avenue Therapeutics打算將淨收益用於一般公司用途，並承諾向美國證券交易委員會提交註冊聲明，轉售行使新認股權證後可發行的股票。
有用
沒用